This page contains a Flash digital edition of a book.
Multiple Sclerosis


30. Evans J, Rogers C, Wiles CM, et al., General practitioners’ prescribing data for multiple sclerosis patients indicates a link with asthma, Br J Gen Pract, 2000;50:323–4.


31. Ponsonby AL, Dwyer T, van der Mei I, et al., Asthma onset prior to multiple sclerosis and the contribution of sibling exposure in early life, Clin Exp Immunol, 2006;146:463–70.


32. Zweiman B, Asthma and autoimmunity: is there a connection?, Curr Allergy Asthma Rep, 2007;7:157-8.


33. Marrie RA, Horwitz RI, Emerging effects of comorbidities on multiple sclerosis, Lancet Neurol, 2010;9:820–8.


34. Caillier SJ, Briggs F, Cree BA, et al., Uncoupling the roles of HLA-DRB1 and HLA-DRB5 genes in multiple sclerosis, J Immunol, 2008;181:5473–80.


35. Australia and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene), Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20, Nat Genet, 2009;41:824–8.


36. Dyment DA, Herrera BM, Cader MZ, et al., Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance, Hum Mol Genet, 2005;14:2019–26.


37. Fernando MM, Stevens CR, Walsh EC, et al., Defining the role of the MHC in autoimmunity: a review and pooled analysis, PLoS Genet, 2008;4:e1000024.


38. Zuvich RL, McCauley JL, Pericak-Vance MA, Haines JL, Genetics and pathogenesis of multiple sclerosis, Semin Immunol, 2009;21:328–33.


39. Suzuki A, Kochi Y, Okada Y, Yamamoto K, Insight from genome-wide association studies in rheumatoid arthritis and multiple sclerosis, FEBS Lett, 2011;585:3627–32.


40. Criswell LA, Pfeiffer KA, Lum RF, et al., Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes, Am J Hum Genet, 2005;76:561–71.


41. Cantorna MT, Vitamin D, multiple sclerosis and inflammatory bowel disease, Arch Biochem Biophys, 2011;November 10 [Epub ahead of print].


42. Freedman MS, Hughes B, Mikol DD, et al., Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison, Eur Neurol, 2008;60:1–11.


43. Goldberg LD, Edwards NC, Fincher C, et al., Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis, J Manag Care Pharm, 2009;15:543–55.


44. Stuart WH, Clinical management of multiple sclerosis: the treatment paradigm and issues of patient management, J Manag Care Pharm, 2004;10:S19–25.


45. Tsang BK, Macdonell R, Multiple sclerosis- diagnosis, management and prognosis, Aust Fam Physician, 2011;40:94–55.


46. Neumann H, Csepregi A, Sailer M, Malfertheiner P, Glatiramer acetate induced acute exacerbation of autoimmune hepatitis in a patient with multiple sclerosis, J Neurol, 2007;254:816–7.


47. Bosca I, Bosca M, Belenguer A, et al., Necrotising cutaneous lesions as a side effect of glatiramer acetate, J Neurol, 2006;253:1370–1.


48. Soós N, Shakery K, Mrowietz U, Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis, Am J Clin Dermatol, 2004;5:357–9.


49. Cicek D, Kandi B, Oguz S, et al., An urticarial vasculitis case induced by glatiramer acetate, J Dermatolog Treat, 2008;19:305–7.


50. Cui G, Zhang Y, Gong Z, et al., Induction of CD4+CD25+Foxp3+ regulatory T cell response by glatiramer acetate in type 1 diabetes, Cell Res, 2009;19:574–83.


51. Zhang M, Chan CC, Vistica B, et al., Copolymer 1 inhibits experimental autoimmune uveoretinitis, J Neuroimmunol, 2000;103:189–94.


52. Borel P, Benkhoucha M, Weber MS, et al., Glatiramer acetate


treatment does not modify the clinical course of (NZB x BXSB)F1 lupus murine model, Int Immunol, 2008;20:1313–9.


53. Zheng B, Switzer K, Marinova E, et al., Exacerbation of autoimmune arthritis by copolymer-I through promoting type 1 immune response and autoantibody production, Autoimmunity, 2008;41:363–71.


54. Durelli L, Bongioanni MR, Ferrero B, et al., Interferon treatment for multiple sclerosis: autoimmune complications may be lethal, Neurology, 1998;50:570–1.


55. Durelli L, Ferrero B, Oggero A, et al., Autoimmune events during interferon beta-1b treatment for multiple sclerosis, J Neurol Sci, 1999;162:74–83.


56. Speciale L, Saresella M, Caputo D, et al., Serum auto antibodies presence in multiple sclerosis patients treated with beta-interferon 1a and 1b, J Neurovirol, 2000;6(Suppl. 2):S57–61.


57. Borg FA, Isenberg DA, Syndromes and complications of interferon therapy, Curr Opin Rheumatol, 2007;19:61–6.


58. Alsalameh S, Manger B, Kern P, Kalden J, New onset of rheumatoid arthritis during interferon beta-1B treatment in a patient with multiple sclerosis: comment on the case report by Jabaily and Thompson, Arthritis Rheum, 1998;41:754.


59. Schott E, Paul F, Wuerfel JT, et al., Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon beta 1a, World J Gastroenterol, 2007;13:3638–40.


60. Blake G, Murphy S, Onset of myasthenia gravis in a patient with multiple sclerosis during interferon-1b treatment, Neurology, 1997;49:1747–8.


61. Rotondi M, Stufano F, Lagonigro MS, et al., Interferon-β but not Glatiramer acetate stimulates CXCL10 secretion in primary cultures of thyrocytes: a clue for understanding the different risks of thyroid dysfunctions in patients with multiple sclerosis treated with either of the two drugs, J Neuroimmunol, 2011;234:161–4.


62. Berkovich RR, Four Cases of Comorbid Multiple Sclerosis and Psoriasis: Sustained Remission of Both Conditions While on Natalizumab, Presented at: American Academy of Neurology 62nd Meeting, Toronto, Canada, April 10–17, 2010;Abstract: P06.163.


63. Crow MK, Type I interferon in organ-targeted autoimmune and inflammatory diseases, Arthritis Res Ther, 2010;12(Suppl. 1):S5.


64. Chen SJ, Wang YL, Fan HC, et al., Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis, Clin Dev Immunol, 2012;2012:970789.


65. Axtell RC, de Jong BA, Boniface K, et al., T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis, Nat Med, 2010;16:406–12.


66. Lee LF, Axtell R, Tu GH, et al., IL-7 promotes T(H)1 development and serum IL-7 predicts clinical response to interferon-β in multiple sclerosis, Sci Transl Med, 2011;3:93ra68.


67. Axtell RC, Raman C, Steinman L, Type I interferons: beneficial in Th1 and detrimental in Th17 autoimmunity, Clin Rev Allergy Immunol, 2012;January 10 [Epub ahead of print].


68. Deltenre P, Peny MO, Dufour A, et al., Acute hepatitis induced by glatiramer acetate, BMJ Case Rep, 2009;2009. pii: bcr09.2008.0913.


69. Von Kalckreuth V, Lohse AW, Schramm C, Unmasking autoimmune hepatitis under immunomodulatory treatment of multiple sclerosis–not only beta interferon, Am J Gastroenterol, 2008;103:2147–8; author reply 2148.


70. Flachenecker P, Autonomic dysfunction in Guillain-Barré syndrome and multiple sclerosis, J Neurol, 2007; 254(Suppl. 2):II96–101.


71. De Jager PL, Graham R, Farwell L, et al., The role of inflammatory bowel disease susceptibility loci in multiple sclerosis and systemic lupus erythematosus, Genes Immun, 2006;7:327–34.


72. Pokorny CS, Beran RG, Pokorny MJ, Association between ulcerative colitis and multiple sclerosis, Intern Med J, 2007;37:721–4.


73. Jawad SH, Askari A, Ward AB, Case history of a patient with multiple sclerosis and scleroderma, Br J Rheumatol, 1997;36:502–3.


74. Trostle DC, Helfrich D, Medsger TA Jr., Systemic sclerosis (scleroderma) and multiple sclerosis, Arthritis Rheum, 1986;29:124–7.


75. Marrosu MG, Cocco E, Lai M, et al., Patients with multiple sclerosis and risk of type 1 diabetes mellitus in Sardinia, Italy: a cohort study, Lancet, 2002;359:1461–5.


76. Becker MD, Heiligenhaus A, Hudde T, et al., Interferon as a treatment for uveitis associated with multiple sclerosis, Br J Ophthalmol, 2005;89:1254–7.


77. Kwok T, Jing Loo W, Guenther L, Psoriasis and multiple sclerosis: is there a link?, J Cutan Med Surg, 2010;14:151–5.


78. Dionisiotis J, Zoukos Y, Thomaides T, Development of myasthenia gravis in two patients with multiple sclerosis following interferon beta treatment, J Neurol Neurosurg Psychiatry, 2004;75:1079.


79. Gharagozli K, Shojaei M, Harandi AA, et al., Myasthenia gravis development and crisis subsequent to multiple sclerosis, Case Report Med, 2011;2011:291731.


80. Ball NJ, Cowan BJ, Hashimoto SA, Lobular panniculitis at the site of subcutaneous interferon beta injections for the treatment of multiple sclerosis can histologically mimic pancreatic panniculitis. A study of 12 cases, J Cutan Pathol, 2009;36:331–7.


81. Poulin F, Rico P, Côté J, Bégin LR, Interferon beta-induced panniculitis mimicking acute appendicitis, Arch Dermatol, 2009;145:916–7.


82. Soares Almeida LM, Requena L, Kutzner H, et al., Localized panniculitis secondary to subcutaneous glatiramer acetate injections for the treatment of multiple sclerosis: a clinicopathologic and immunohistochemical study, J Am Acad Dermatol, 2006;55:968–74.


83. López-Lerma I, Iranzo P, Herrero C, New-onset psoriasis in a patient treated with interferon beta-1a, Br J Dermatol, 2009;160:716–7.


84. La Mantia L, Capsoni F, Psoriasis during interferon beta treatment for multiple sclerosis, Neurol Sci, 2010;31:337–9.


85. Navne JE, Hedegaard U, Bygum A, [Activation of psoriasis in patients undergoing treatment with interferon-beta], Ugeskr Laeger, 2005;167:2903–4.


86. Rodrigues S, Magro F, Soares J, et al., Case series: ulcerative colitis, multiple sclerosis, and interferon-beta 1a, Inflamm Bowel Dis, 2010;16:2001–3.


87. Tuna Y, Basar O, Dikici H, Köklü S, Rapid onset of ulcerative colitis after treatment with interferon β1a in a patient with multiple sclerosis, J Crohns Colitis, 2011;5:75–6.


88. Palao-Duarte S, Corral-Corral I, Zarza B, Costa-Frossard L, [Ulcerative colitis in a female patient with multiple sclerosis receiving treatment with interferon], Rev Neurol, 2005;41:319–20.


89. Daza-Barriga JS, [Small vessel vasculitis associated with the use of interferon beta-1a in multiple sclerosis], Rev Neurol, 2008;46:702–3.


90. Débat Zoguéreh D, Boucraut J, Beau-Salinas F, et al., [Cutaneous vasculitis with renal impairment complicating interferon-beta 1a therapy for multiple sclerosis], Rev Neurol (Paris), 2004;160:1081–4.


91. Szilasiová J, Gdovinová Z, Jautová J, et al., Cutaneous vasculitis associated with interferon beta-1b treatment for multiple sclerosis, Clin Neuropharmacol, 2009;32:301–3.


92. Bonaci-Nikolic B, Jeremic I, Andrejevic S, et al., Anti-double stranded DNA and lupus syndrome induced by interferon-beta therapy in a patient with multiple sclerosis, Lupus, 2009;18:78–80.


138


US NEUROLOGY


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108